Corvus Pharmaceuticals OverviewCorvus Pharmaceuticals Other Income Expense Net
Other Income/Expense Net for CRVS.
Quarterly Other Income/Expense
$1.19M
↓ 95.28% YoY
As of Mar 31, 2026
Annual Other Income/Expense (TTM)
$3.76M
↑ 136.91% YoY
Trailing 12 months ending Mar 31, 2026